HGF/Met pathway has been suggested to act as a resistance mechanism against EGFR inhibition in advanced HNSCC and co-targeting both receptors has demonstrated improved ability to sensitize cells to cetuximab [102]. The gene discussed is MET; the disease is head and neck squamous cell carcinoma.